Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

Authors: Elias Jabbour, Hagop M. Kantarjian, Farhad Ravandi, Deborah A. Thomas, Xuelin Huang, Stefan Faderl, Naveen Pemmaraju, Naval Daver, Guillermo Garcia‐Manero, Koji Sasaki, Jörge E. Cortes, Rebecca Garris, C. Cameron Yin, Joseph D. Khoury, Jeffrey L. Jorgensen, Zeev Estrov, Zachary S. Bohannan, Marina Konopleva, Tapan M. Kadia, Nitin Jain, Courtney D. DiNardo, William G. Wierda, Vicky Jeanis, Susan O’Brien - The Lancet 2015 cited by 280